Evaluation of Postmenopausal Bleeding
Initial Diagnostic Approach
- The American College of Radiology recommends transvaginal ultrasound (TVUS) as the first-line imaging test for women with postmenopausal bleeding to measure endometrial thickness and identify structural abnormalities of the uterus, endometrium, and ovaries 1, 2
- An endometrial thickness of ≤4 mm on TVUS has a negative predictive value for cancer of nearly 100% 1, 2
- If endometrial thickness is ≥5 mm, endometrial tissue sampling is indicated 1, 2
- Office endometrial biopsy is the standard method for obtaining tissue for histological assessment, with a false-negative rate of approximately 10% 1
Follow-up Evaluation
- If office endometrial biopsy is negative but bleeding persists, or if the biopsy is non-diagnostic, a fractional dilation and curettage (D&C) under anesthesia should be performed 1
- Hysteroscopy may be helpful in evaluating the endometrium for lesions such as polyps in patients with persistent or recurrent undiagnosed bleeding 1
- MRI can be considered if TVUS cannot adequately evaluate the endometrium due to patient factors or pathology, such as fibroids or adenomyosis 1
Why Pap Smear Is Not Indicated
- The American Journal of Obstetrics and Gynecology states that Pap smear is designed to screen for cervical cancer, not endometrial cancer or other causes of postmenopausal bleeding 3
- Cervical cancer screening guidelines recommend Pap tests every 3-5 years depending on age and HPV co-testing, but not specifically for the evaluation of postmenopausal bleeding 4
- The primary concern with postmenopausal bleeding is endometrial cancer, which is not reliably detected by Pap smear 3, 5, 1
Important Considerations
- In postmenopausal patients with abnormal uterine bleeding, even in the presence of fibroids, uterine sarcoma and endometrial cancer must be ruled out 1
- The risk of unexpected uterine sarcoma is higher in older patients, up to 10.1 per 1,000 in patients 75-79 years of age 1
- Postmenopausal women taking selective estrogen receptor modulators (SERMs) like tamoxifen should be advised to report any vaginal spotting or bleeding, as these drugs slightly increase the risk of endometrial cancer 4
Clinical Pitfalls to Avoid
- Relying solely on Pap smear for evaluation of postmenopausal bleeding may miss endometrial pathology 3, 1
- Using endometrial thickness cutoffs higher than 4 mm may miss cases of endometrial cancer 2, 1
- Failing to pursue further evaluation when initial tests are negative but bleeding persists 1
Evaluation of Postmenopausal Bleeding
Diagnostic Approach
- The National Comprehensive Cancer Network recommends that if office endometrial biopsy is negative but bleeding persists, or if the biopsy is non-diagnostic, a fractional dilation and curettage (D&C) under anesthesia should be performed 6
- The National Comprehensive Cancer Network suggests that in patients with extrauterine disease, a serum CA-125 assay may be helpful in monitoring clinical response, though it has limitations 6
Diagnostic Tools
- Hysteroscopy should be used as the final step in the diagnostic pathway for women with postmenopausal bleeding, especially when structural abnormalities are suspected 7
- Saline infusion sonography can be used to distinguish between focal and diffuse pathology 7
Etiologies of Postmenopausal Vaginal Bleeding
Malignant and Benign Etiologies
- Endometrial cancer is the most serious etiology and must be excluded first, though most postmenopausal bleeding has a benign cause, according to the American College of Radiology 8
- Ovarian cancer may present with bleeding, particularly hormone-producing ovarian tumors, as reported by the American College of Radiology 9
- Endometrial polyps are common structural causes that can be visualized on transvaginal ultrasound or hysteroscopy, as noted by the American College of Radiology 8
- Endometrial hyperplasia (with or without polyps) represents a precursor to endometrial cancer and requires tissue diagnosis, according to the American College of Radiology 8
- Cervical stenosis with hematometra can cause bleeding when the obstruction releases, as reported by the American College of Radiology 9, 10
- Chronic pelvic inflammatory disease with hydrosalpinx or pyosalpinx may contribute to bleeding, as noted by the American College of Radiology 9, 11